| Literature DB >> 26101573 |
William T McElroy1, Zheng Tan1, Ginny Ho1, Sunil Paliwal1, Guoqing Li1, W Michael Seganish1, Deen Tulshian1, James Tata1, Thierry O Fischmann1, Christopher Sondey1, Hong Bian1, Loretta Bober1, James Jackson1, Charles G Garlisi1, Kristine Devito1, James Fossetta1, Daniel Lundell1, Xiaoda Niu1.
Abstract
IRAK4 is a critical upstream kinase in the IL-1R/TLR signaling pathway. Inhibition of IRAK4 is hypothesized to be beneficial in the treatment of autoimmune related disorders. A screening campaign identified a pyrazole class of IRAK4 inhibitors that were determined by X-ray crystallography to exhibit an unusual binding mode. SAR efforts focused on the identification of a potent and selective inhibitor with good aqueous solubility and rodent pharmacokinetics. Pyrazole C-3 piperidines were well tolerated, with N-sulfonyl analogues generally having good rodent oral exposure but poor solubility. N-Alkyl piperidines exhibited excellent solubility and reduced exposure. Pyrazoles possessing N-1 pyridine and fluorophenyl substituents were among the most active. Piperazine 32 was a potent enzyme inhibitor with good cellular activity. Compound 32 reduced the in vivo production of proinflammatory cytokines and was orally efficacious in a mouse antibody induced arthritis disease model of inflammation.Entities:
Keywords: Interleukin-1 receptor-associated kinase 4; SAR; drug discovery; inflammation; structure-based drug design
Year: 2015 PMID: 26101573 PMCID: PMC4468401 DOI: 10.1021/acsmedchemlett.5b00106
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345